Copyright: © 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies. The findings of the ...

"Long Live Rock" this week at Acrisure Arena. Two nights after Paul McCartney kicked off his Got Back North American Tour 2025 at the venue, The Who performed on the same desert stage. The group's Oct ...

Men with aggressive prostate cancer who were being treated with a groundbreaking drug have been told the therapy is no longer available at public hospitals. Lutetium PSMA was being compounded locally, ...

John Mara, the 70-year-old president, chief executive officer and co-owner of the Giants, has recently been diagnosed with cancer. He is undergoing treatment, according to a statement he released ...

Bryce Vissel does not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and has disclosed no relevant affiliations beyond their ...

People affected by Huntington’s disease could at last benefit from the first treatment to slow the fatal neurodegenerative condition. Scientists from University College London (UCL) found patients ...

Cancer cells can brainwash their neighbors. Like the CIA deploying secret agents to turn an enemy, tumors use a similar strategy to manipulate nearby cells. The tumors’ agents are mitochondria, the ...

Danish biotechnology company Genmab GMAB0.90%increase; green up pointing triangle agreed to buy Nasdaq-listed cancer-treatment developer Merus for around $8 billion in cash, as it looks to bolster its ...

EAST RUTHERFORD − John Mara once told me that his legacy with the New York Giants and how he was ultimately perceived as team president is not what makes him nervous. There is little debate that ...

New York Giants co-owner John Mara was diagnosed with cancer, he announced Monday. Mara, 70, said he plans to remain active with the team as he undergoes treatment. Mara announced his diagnosis in a ...

The centerpiece of the acquisition is petosemtamab, Merus’ bispecific antibody targeting EGFR and LGR5, which in May demonstrated best-in-class potential for head-and-neck cancer. Genmab has won the ...

aDepartment of Respiratory Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan bDepartment of Respiratory Medicine and Infectious Diseases, Niigata University Graduate School of ...